Acorda Therapeutics Inc (ACOR):企業の財務・戦略的SWOT分析

◆英語タイトル:Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1096
◆発行会社(調査会社):GlobalData
◆発行日:2020年2月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Acorda Therapeutics Inc (ACOR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS) and for the intermittent treatment of people with Parkinson’s taking carbidopa or levodopa who experience off episodes. It is also developing a pipeline of neurological therapies addressing a range of disorders, including migraine, MS, heart failure and spinal cord injury. The company sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc Key Recent Developments

Feb 13,2020: Acorda Therapeutics provides business update and reports fourth quarter and full year 2019 financial results
Jan 15,2020: Acorda provides 2019 highlights and 2020 guidance at J.P. Morgan Healthcare Conference
Nov 27,2019: Acorda Therapeutics elects John Kelley Chair, Board of Directors
Nov 12,2019: Acorda Therapeutics announces departure of President, International & General Counsel
Nov 04,2019: Acorda provides update for third quarter ended september 30, 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Acorda Therapeutics Inc – Key Facts
Acorda Therapeutics Inc – Key Employees
Acorda Therapeutics Inc – Key Employee Biographies
Acorda Therapeutics Inc – Major Products and Services
Acorda Therapeutics Inc – History
Acorda Therapeutics Inc – Company Statement
Acorda Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Acorda Therapeutics Inc – Business Description
Product Category: Ampyra
Overview
Performance
Product Category: Inbrija
Overview
Product Category: Qutenza
Overview
Performance
Product Category: Net Product Revenue
Capital Expenditure
Product Category: Royalty Revenue
Performance
R&D Overview
Acorda Therapeutics Inc – Corporate Strategy
Acorda Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Acorda Therapeutics Inc – Strengths
Acorda Therapeutics Inc – Weaknesses
Acorda Therapeutics Inc – Opportunities
Acorda Therapeutics Inc – Threats
Acorda Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Acorda Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 13, 2020: Acorda Therapeutics provides business update and reports fourth quarter and full year 2019 financial results
Jan 15, 2020: Acorda provides 2019 highlights and 2020 guidance at J.P. Morgan Healthcare Conference
Nov 27, 2019: Acorda Therapeutics elects John Kelley Chair, Board of Directors
Nov 12, 2019: Acorda Therapeutics announces departure of President, International & General Counsel
Nov 04, 2019: Acorda provides update for third quarter ended september 30, 2019
Oct 23, 2019: Acorda Therapeutics implements corporate restructuring, provides third quarter 2019 update
Oct 22, 2019: Acorda launches new tool for people with Parkinson’s to improve communication about off periods
Aug 01, 2019: Acorda provides update for second quarter ended June 30, 2019
Jun 28, 2019: $21.9 Million gene modulation research effort targets influenza pandemics
Jun 03, 2019: Acorda Therapeutics Debuts Art Exhibition inspired by people with Parkinson’s at the 5th World Parkinson Congress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Acorda Therapeutics Inc, Key Facts
Acorda Therapeutics Inc, Key Employees
Acorda Therapeutics Inc, Key Employee Biographies
Acorda Therapeutics Inc, Major Products and Services
Acorda Therapeutics Inc, History
Acorda Therapeutics Inc, Other Locations
Acorda Therapeutics Inc, Subsidiaries
Acorda Therapeutics Inc, Key Competitors
Acorda Therapeutics Inc, Ratios based on current share price
Acorda Therapeutics Inc, Annual Ratios
Acorda Therapeutics Inc, Annual Ratios (Cont...1)
Acorda Therapeutics Inc, Annual Ratios (Cont...2)
Acorda Therapeutics Inc, Interim Ratios
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Acorda Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Acorda Therapeutics Inc, Performance Chart (2015 - 2019)
Acorda Therapeutics Inc, Ratio Charts
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Acorda Therapeutics Inc (ACOR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tupperware Brands Corp (TUP):企業の財務・戦略的SWOT分析
    Tupperware Brands Corp (TUP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • NGEx Resources Inc:企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Teradyne Inc (TER):企業の財務・戦略的SWOT分析
    Teradyne Inc (TER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Solon Eiendom ASA (SOLON):企業の財務・戦略的SWOT分析
    Solon Eiendom ASA (SOLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Techtronic Industries Co Ltd (669):企業の財務・戦略的SWOT分析
    Techtronic Industries Co Ltd (669) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • CTI BioPharma Corp (CTIC)-製薬・医療分野:企業M&A・提携分析
    Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or r …
  • Cabot Corp (CBT):企業の財務・戦略的SWOT分析
    Cabot Corp (CBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Petroleo Brasileiro SA (PETR4):企業の財務・戦略的SWOT分析
    Petroleo Brasileiro SA (PETR4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Verseon Corp (VSN):企業の財務・戦略的SWOT分析
    Summary Verseon Corp (Verseon) is a pharmaceutical company that develops novel therapeutics. The company develops drug programs in the therapeutic areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. Its anticoagulation program develops oral anticoagulants for cardi …
  • Vital Therapies Inc (VTL)-製薬・医療分野:企業M&A・提携分析
    Summary Vital Therapies Inc (Vital Therapies) is a biotherapeutic company that develops cell-based therapy treatment for acute forms of liver failure. The company offers ELAD system, a human hepatic cell-based liver support system designed to liver function in patients with life-threatening, acute l …
  • Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates:企業の戦略・SWOT・財務分析
    Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report Summary Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Shopping Centres Australasia Property Group RE Limited:企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Impel NeuroPharma Inc:医療機器:M&Aディール及び事業提携情報
    Summary Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delive …
  • PT Pertamina (Persero):企業の戦略・SWOT・財務分析
    PT Pertamina (Persero) - Strategy, SWOT and Corporate Finance Report Summary PT Pertamina (Persero) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Obton AS-エネルギー分野:企業M&A・提携分析
    Summary Obton A/S (Obton) is an investment company that specializes in management of assets within renewable energy. The company's investment process include screening process which inludes verification of prerequisites such as financial terms, amount of irradiation, power purchase agreement and fee …
  • Orion Diagnostica Oy:医療機器:M&Aディール及び事業提携情報
    Summary Orion Diagnostica Oy (Orion Diagnostica), a subsidiary of Orion Oyj, is a medical equipment company that develops, manufactures clinical diagnostic and hygiene monitoring tests. Its product portfolio provides diagnosis and treatment management kits, point of care systems, ready to use kits, …
  • Hyatt Hotels Corporation:企業の戦略・SWOT・財務情報
    Hyatt Hotels Corporation - Strategy, SWOT and Corporate Finance Report Summary Hyatt Hotels Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Finning International Inc. (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc. (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Hon Hai Precision Industry Co Ltd (2317):企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • TDK Corporation:戦略・SWOT・企業財務分析
    TDK Corporation - Strategy, SWOT and Corporate Finance Report Summary TDK Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆